
Kodiak Sciences, Moderna, and Danaher are the three Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of companies that develop products and technologies based on biology, such as medicines, vaccines, diagnostics, and gene therapies. For investors, these stocks can offer significant growth potential but often carry higher risk because their performance may depend on clinical-trial results, regulatory approvals, and substantial research-and-development costs. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.
Kodiak Sciences (KOD)
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.
Moderna (MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.
Read Our Latest Research Report on MRNA
Danaher (DHR)
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read Our Latest Research Report on DHR
Recommended Stories
- MarketBeat’s Top Five Stocks to Own in September 2026
- 3 Healthcare Stocks Showing Why the Sector Still Has Momentum
- Akamai’s Anthropic Deal Puts $5.5 Billion Behind Its Edge AI Pivot
- 3 Stocks Under the Microscope After Large Insider Sales
- The Nasdaq Nears a Major Breakout: 5 Tech ETFs to Play the Move
- AST SpaceMobile’s New Securities Lawsuit Adds Fuel to an Already Volatile Stock
